Program
rezatapopt
Also written as “PC14586” and “[14C]-PC14586”.
Its studies are mostly in Neoplasm Metastasis, led by PMV Pharmaceuticals.
Furthest: phase 2, since Oct 1, 20205 company-led studies, 2 open or runningNext primary completion: Dec 15, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| PMV Pharmaceuticals | 52 open or running | phase 2since Oct 1, 2020 | Oct 1, 2020 | Dec 15, 2026phase 2 · NCT04585750 |
Also a collaborator on its studies: Merck.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 1, 2020First study: phase 2 study in Neoplasm MetastasisFirst studyNCT04585750 · 300 planned · United States, Australia, France and more
- Jan 7, 2022Phase 1 study in Healthy VolunteersNCT05249348 · 34 enrolled · United States
- Aug 22, 2022Phase 1 study in Healthy Male VolunteersNCT05523687 · 8 enrolled · United States
- Mar 25, 2024Phase 1 study in Healthy VolunteersNCT06362642 · 12 enrolled · United States
- Jan 5, 2026Phase 1 study in TP53 Y220C MutationNCT07372625 · 14 planned · United States
Ahead
- Dec 15, 2026Primary completion: phase 2 study in Neoplasm MetastasisNCT04585750
- Mar 2027Primary completion: phase 1 study in TP53 Y220C MutationNCT07372625
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07372625TP53 Y220C Mutation · United States | 1 | Recruiting | Mar 2027 | 14 |
| NCT06362642Healthy Volunteers · United States | 1 | Completed | Oct 22, 2024 | 12 |
| NCT05523687Healthy Male Volunteers · United States | 1 | Completed | Nov 30, 2022 | 8 |
| NCT05249348Healthy Volunteers · United States | 1 | Completed | Jun 9, 2022 | 34 |
| NCT04585750Neoplasm Metastasis · United States, Australia, France and more | 2 | Recruiting | Dec 15, 2026 | 300 |
How it is read
Names in the registry
- “rezatapopt”, 2 entries
- “PC14586”, 2 entries
- “[14C]-PC14586”, 1 entry
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.